M&A / Deals Oxford BioTherapeutics signs collaboration with Bristol Myers Squibb PharmaTimesPartnership to develop nextgeneration Tcell engagers for solid tumoursM&A / DealsRead full story pharminent April 9, 2026 (Last updated: April 9, 2026) PharmaTimes Partnership to develop nextgeneration Tcell engagers for solid tumours M&A / DealsRead full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Innovent’s CDMO gets green light to make biologics at large Chinese plantNext: Avalyn plots IPO to push inhaled pulmonary fibrosis pipeline through clinic Related Stories M&A / Deals Fulcrum exploring a potential sale after FDA sidelined its sickle cell drug pharminent June 2, 2026 M&A / Deals CordenPharma inks AmbioPharm buyout to continue peptide production expansion pharminent June 1, 2026 M&A / Deals Servier wagers $2.65bn on Edgewise muscular dystrophy drug pharminent June 1, 2026
